ABSTRACT
Approximately 30,000 patients in the United States 1 and over 100,000 patients worldwide 2 receive solid organ transplants annually, and the incidence of solid organ transplantation has been steadily increasing each year. With the introduction of new medications to prevent acute rejection and other medical advances, maintenance of allografts in transplant recipients has significantly improved over the past 2 decades. This improved survival results in the development of additional morbidities, including an increased risk for malignancies, largely owing to immunosuppressive medications used to prevent graft rejection. 3, 4 Common malignancies observed in solid organ transplant recipients include skin carcinomas, Kaposi sarcoma, and renal cell carcinoma. 5 Among hematolymphoid neoplasms, posttransplant lymphoproliferative disorder (PTLD) constitutes a major component, occurring in 2% to 10% of solid organ transplant recipients, 6 making it second among all types of posttransplant malignancy, only after skin carcinomas. 4, 5 In contrast, other hematolymphoid neoplasms, such as myeloid neoplasms occurring after solid organ transplantation, are rare. Reports of these diseases are limited mostly to a few small series and epidemiologic studies in the literature. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] The clinicopathologic features of myeloid neoplasm (MN) following organ transplantation, including the specific incidence, subtype spectrum, pattern of cytogenetic abnormalities, underlying molecular changes, therapeutic response, and clinical outcome, have not been well characterized. Herein, we report a retrospective analysis of 23 cases of MN developed subsequent to solid organ transplantation, with a focus on the pathologic features and clinical outcomes.
Materials and Methods

Case Selection
Twenty-three cases of MN were identified from our bone marrow biopsy database using the search terms leukemia, myelodysplastic, myeloid neoplasm, or myeloproliferative, in combination with kidney transplant, heart transplant, liver transplant, or lung transplant. These included 16 cases from Duke University Medical Center (with a total of 2,797 solid organ transplants between 1999 and 2009), six cases from the University of California at San Francisco, and one case from Thomas Jefferson University Medical Center. The cases were reviewed independently by three authors (E.W., J.G., and C.M.L.). The diagnoses of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or other MNs were confirmed according to the 2016 revision to the World Health Organization classification. 24, 25 The primary diagnosis, transplant history, medications used for graft maintenance, treatment for MN, other clinical information, and laboratory data for flow cytometry and cytogenetic studies were collected from our respective health information systems and retrospectively reviewed.
Statistical Analysis
The statistical analyses were performed with IBM SPSS Statistics, version 24 (SPSS, Chicgao, IL). Analysis of variance was applied to test the difference of latencies among the groups, stratified by types of solid organ transplant or by types of leukemia, and Student t test was used to analyze the difference between the two groups. Overall survival was calculated using Kaplan-Meier survival analysis, generating the estimated median survival and a 95% confidence interval.
Results
❚Table 1❚ summarizes the clinical features in 23 cases of MN following solid organ transplantation, and ❚Table 2❚ summarizes the pathologic features and clinical outcomes in these 23 cases.
Clinical Information
Of the 23 cases of MN identified in patients with a history of solid organ transplantation, 15 were male patients, and eight were female patients ( Table 1) . The patients' ages at the time of diagnosis ranged from 2 to 76 years, with a median of 59 years (mean [SD] , 54 [15.8] years). The transplanted organs included kidney in six, liver in five, lung in five, heart in six, and combined heart/lung transplantation in one patient(s). Ten of the donors were unrelated to the respective recipients, while two were sibling donors, and the remaining 11 cases lacked donor information. Of 23 patients, five had autoimmune or autoimmune-like conditions as primary disease resulting in corresponding organ failure, including primary sclerosing cholangitis (n = 2), glomerulonephritis (n = 2), and Wegener granulomatosis (n = 1). The remaining patients had organ failure due to causes other than autoimmune disease. Of the patients with autoimmune diseases, two had received antimetabolites, including mercaptopurine in patient 4 and cyclophosphamide in patient 9, but the doses and course of the treatments were not detailed. The remaining cases did not have treatment information provided in the clinical notes due to transferring care from other institutions. Posttransplant immunosuppressive regimens included tacrolimus and mycophenolate mofetil in most of our patients, with the addition of prednisone or related regimens in 16 cases, cyclosporine in three cases, azathioprine in four cases, and cyclophosphamide in two cases. During the latency period, 13 patients received three or more immunosuppressive regimens, nine patients received one or two immunosuppressive regimens, and the remaining one patient did not have the pertinent information provided in the medical record. Table 1 ). However, this difference is not statistically significant (P = .06). All patients with AML and MDS had cytopenia, while the patients with CML or other MPNs had leukocytosis and/or thrombocytosis, leading to the bone marrow examinations and subsequent diagnoses of MN (Table 2 ).
Cytomorphologic and Histologic Evaluation
Of 12 cases of posttransplant AML/MPAL, 10 cases demonstrated circulating blasts in the peripheral blood smear, accounting for 1%-2% to 30% of total leukocytes. The remaining two cases of AML showed pancytopenia without circulating blasts (Table 2 ). Eleven cases demonstrated more than 20% blasts or blast equivalents in the bone marrow. The remaining case of AML (case 4) showed only 4% blasts in the bone marrow biopsy specimen, with 1% to 2% blasts in the peripheral blood smear. In this case, the diagnosis of AML was established by the detection of a clonal karyotypic Thereafter, the diagnoses of MDS were established for both cases. All patients diagnosed with CML had marked leukocytosis with left-shifted neutrophilia and absolute basophilia in the peripheral blood smear review. In addition, these cases exhibited myeloid hyperplasia with proliferation of small megakaryocytes with no increase in blasts in the bone marrow. These morphologic features were characteristic of CML, chronic phase. In case 18, the peripheral blood smear showed leukocytosis with marked eosinophilia, and the bone marrow biopsy specimen demonstrated hypercellularity with myeloid hyperplasia, marked eosinophilia, and abnormal mastocytosis. The diagnosis of myeloproliferative neoplasm with eosinophilia was eventually confirmed by a molecular diagnostic test. Review of the peripheral blood findings in case 19 showed marked neutrophilia and thrombocytosis, and a bone marrow biopsy specimen demonstrated hypercellularity with myeloid and megakaryocytic hyperplasia. In this case, megakaryocytes formed clusters with many large hyperlobate forms. These morphologic features were characteristic of essential thrombocythemia, consistent with this patient's progressive thrombocytosis (927,000/µL).
Flow Cytometric Analysis and Immunohistochemical Analysis
Flow cytometry were performed in 11 of the AML/ MPAL cases (flow cytometry was not performed in case 9). Ten of the bone marrow flow cytometric analyses (all of the AML/MPAL cases, apart from case 4) demonstrated increased blasts with a myeloid immunophenotype. In case 12, flow cytometric analysis demonstrated a blast population with mixed expression of myeloid (CD117 and CD13) and B-cell (CD19, partial CD20, and partial CD22) antigens. Due to the ambiguous phenotype by flow cytometric analysis, immunohistochemical analysis was performed, which showed expression of PAX5, TdT, partial CD79a, partial MPO, partial CD15, and CD68 in the blast population. The immunophenotypic profile was consistent with the diagnosis of MPAL in this case. Case 4 did not have significantly increased blasts detected by flow cytometry, while 4% blasts were morphologically identified in the bone marrow aspirate smear. Four cases ❚Figure 1❚ Distribution of leukemia types and latency periods among different types of solid organ transplants. AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MN, myeloid neoplasm; MPN, myeloproliferative neoplasm.
of MDS had flow cytometry performed, and only case 14 demonstrated mildly increased myeloblasts (8% of the total analyzed events). Of the cases of MDS, 2 demonstrated phenotypic alterations suggestive of dyspoiesis, including aberrant expression of CD56 in monocytes and granulocytes, downregulation of HLA-DR in monocytes, aberrant expression of HLA-DR in granulocytes (case 17), and downregulation of CD10 in granulocytes (case 16) . No increase in blasts was identified in three CML cases and one MPN case in which flow cytometry was performed.
Cytogenetic Analysis and Molecular Diagnostic Studies
Conventional cytogenetic analyses were performed on bone marrow specimens from all 23 cases of posttransplant MN. Of these, 18 (78.3%) cases demonstrated clonal cytogenetic abnormalities, while five cases showed a normal karyotype ❚Figure 2❚. Of the 18 cases with clonal cytogenetic abnormalities, 12 were cases of acute leukemia, two were cases of MDS, and four were cases of CML. The types of cytogenetic abnormalities observed include complex cytogenetic abnormalities in four cases (all were AML), 5q deletion in two cases (both were AML), monosomy 7 or 7q deletion in three cases, 11q23 rearrangement in three cases (all were AML), inversion 16 in one case, isolated Philadelphia chromosome in four cases of CML, and trisomy 13 in one case of MPAL. Of the cases with cytogenetic abnormalities, cases with balanced changes accounted for eight (44.4%), and those with unbalanced changes accounted for 10 (55.6%). The presence of BCR/ABL1 fusion had been confirmed by fluorescence in situ hybridization (FISH) analysis in all cases of CML. Three cases of CML tested for BCR/ ABL1 fusion transcripts showed b3a2 fusion products. Excluding CML and MPN, the rate of cytogenetic abnormalities in acute leukemia and MDS is 82.4% (14/17). Of the 14 cases of acute leukemia and MDS with cytogenetic abnormalities, 10 (71.4%) harbored unbalanced chromosomal aberrations, including 5q deletion, monosomy 7/7q deletion, and complex cytogenetic abnormalities; the other four (28.6%) cases harbored balanced chromosomal changes, including rearrangement of 11q23 (MLL) locus in three cases and inv (16) using the characteristic morphologic features and clinical findings of progressive thrombocytosis. Of the three cases of MDS with a normal karyotype, the diagnosis was supported by increased blasts in one case (case 14) and by prominent myelodysplasia in two cases (cases 13 and 16) ( Table 2) .
Treatment for MNs and Clinical Outcome
Treatment information was available for 20 patients, and all patients apart from one had follow-up information available. The median follow-up was 7 months with a range of 0.5 to 88 months. All cases of acute leukemia but one were treated with combination chemotherapy, including mostly cytarabine and daunorubicin/derivative-based regimens. Case 12 was treated with an adult acute lymphoblastic leukemia protocol. One patient with AML (case 2) was treated with supportive care due to the patient's unstable medical condition. Of the 12 patients with acute leukemia, seven died of leukemia, with an estimated median survival of 3.5 months (95% confidence interval [CI], 0-14.3 months) ❚Figure 3A❚. Of the five patients with acute leukemia who were alive at the last follow-up, two patients eventually received intensified chemotherapy followed by allogeneic hematopoietic stem cell transplantation (case 7) and autologous hematopoietic stem cell transplantation (case 6), respectively. One patient (case 5) underwent a clinical trial using liposomal delivery of chemotherapy, but this patient subsequently had a relapse noted at the time of last follow-up. Only two patients who developed MDS had treatment information available; one patient received 5-aracitidine (case 14) , and the other patient received supportive care (case 15). All five patients with MDS but one died due to the disease progression, with an estimated median survival of 7 months (95% CI, 5.3-8.8 months) ( Figure 3A ). Patient 13 died of multiorgan failure related to a transplant complication rather MDS and thus was censored at the time of death. Collectively, the patients with acute leukemia or MDS (17 cases) demonstrated an estimated median survival of 7 months (95% CI, 2.4-11.6 months) ❚Figure 3B❚. Both cases of MPN were treated with hydoxyurea. Case 18 was also treated with imatinib because of abnormal mastocytosis observed in the bone marrow with marked elevation of serum tryptase. This patient responded well to the treatment and was alive with clinical remission up to the time when this manuscript was prepared. Patient 19 died of multiorgan failure 63 months after the diagnosis of essential thrombocytosis, when the hematologic neoplasm was clinically well controlled. All four patients with CML were treated with imatinib. Two of these patients (cases 20 and 21) had difficulties with treatment compliance. Although their diseases appeared to be in hematologic and morphologic remission, both patients subsequently demonstrated positivity for BCR/ ABL1 fusion, either by RT-PCR or interphase FISH analysis. Survival analysis for MPN and CML could not be performed due to the lack of cases with cause-specific terminal events ( Figure 3A) .
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❚Figure 3❚ Kaplan-Meier survival analyses. A, Cause-specific survival analysis with stratification of leukemia types. Two patients who died of competing causes rather than posttransplant leukemia were censored at the times of death (patient 13 at 75 months and patient 19 at 63 months) in the analysis. B, Cause-specific survival analysis of 17 patients with either posttransplant AML or MDS. AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MN, myeloid neoplasm; MPN, myeloproliferative neoplasm.
Discussion
While the risks for developing malignancies, such as lymphoproliferative disorders 2, 5, 6 and skin carcinomas, 5 are significantly increased in solid organ transplant recipients, MNs following solid organ transplantation are relatively infrequent, and their association with transplantation is poorly characterized. An initial epidemiologic study suggested that the incidence of AML in solid organ transplant recipients was not significantly increased compared with that seen in the general population, 26 but recent investigations demonstrated evidence of an increased risk for the development of MN in solid organ transplant recipients. [7] [8] [9] 23 The overall risk for MN, although lower than that for lymphoma, is estimated at 2-to 3-fold in solid organ transplant recipients compared with the control population. 22, 23 Morton et al 7 studied MNs occurring in 207,859 solid organ transplant recipients and showed that this particular patient population had a substantially increased risk for the development of MN, with a 2.7-fold increased risk for AML, a 4.6-fold increased risk for MDS, a 2.3-fold increased risk for CML, and a 7.2-fold increased risk for polycythemia vera. The risk for the development of MN varied with the type of organ transplanted; the highest risk for MDS was observed in patients who had received lung transplantation. Similarly, a large cohort study performed by Offman et al 9 identified 37 cases of AML in 31,691 recipients of lung, heart, or combined heart/lung transplants and 56 cases of AML in 153,528 recipients of kidney transplants. In this study, they were able to demonstrate that the relative risk for AML was 5.5 for heart/lung transplant recipients and 2.1 for kidney transplant recipients compared with the age-matched control population. Although kidney transplantation comprises over half of the total solid organ transplantation procedures and results in a life expectance longer than that seen after other solid organ transplantation, the resulting MNs in patients following kidney transplant comprised only onefourth of the total posttransplant MNs in our series. More than half of the patients in our series had received either lung or heart transplants, a proportion similar to that seen in previous studies. 7, 9 This distribution among the types of transplanted organs is likely due to the higher intensity immunosuppressive regimens used in thoracic organ transplantation. 7 Interestingly, the median age for CML diagnosis in our series was 45 years with a range of 35 to 60 years, which is significantly younger than that seen in the de novo CML. The much younger age observed in the patients with posttransplant CML (median, 39 years; range, 8-63 years) was also reported by le Coutre et al 13 in their case series. Significantly younger ages were also observed in posttransplant MDS (median, 58 years; range, 42-65 years) and other MNs in our series and reported in the previous study. 11 Our case series, in addition to the recent epidemiologic data, supports an association of MNs with solid organ transplantation and suggests that development of MN may be accelerated by the transplantation itself or by the immunosuppressive medications used to promote graft tolerance. However, many questions remain unanswered: are there differences in the pathologic features of MNs in this particular patient population compared with the de novo counterpart in the general population? Do the clinical and pathologic features, such as the disease spectrum, latency, and cytogenetic profile, resemble those observed in conventional therapy-related MNs? Of the patients diagnosed with acute leukemia in our series, all exhibited clonal cytogenetic abnormalities, and of the cases with acute leukemia or MDS, 82.4% demonstrated clonal cytogenetic abnormalities, the majority of which (92.9%) harbored complex changes, interstitial deletion of chromosome 5q, loss or partial loss of chromosome 7, or rearrangement of chromosome 11q23. According to the recent literature, clonal cytogenetic abnormalities are identified in 40% to 60% of de novo AML, 27, 28 and a similar rate is reported in de novo MDS. 29, 30 In de novo AML and MDS, cytogenetic abnormalities involving 5q or 7q deletion and complex abnormalities comprise 30% to 40% of the total cases with clonal cytogenetic abnormalities, and 11q23 rearrangement is a rare finding (2%-4%). The high fraction of cases demonstrating cytogenetic abnormalities and the profile of abnormalities seen in our case series differ from those reported in de novo AML/MDS. Rather, the cytogenetic profile in these cases is similar to that described in conventional therapy-related AML/MDS. 31 In our series, slightly more than half (55.6%) of the cases with cytogenetic abnormalities harbored unbalanced changes, and the remaining cases had balanced changes. Excluding the cases of CML, twothirds of the cases with clonal cytogenetic abnormalities harbored unbalanced changes, and one-third harbored balanced changes. The features of cytogenetic aberrations are suggestive of a mutagenic effect on the development of MNs after solid organ transplantation. The latency period in our case series falls between the latency periods seen in AML/MDS associated with alkylating agents/ionizing radiation and that associated with topoisomerase II inhibitors, possibly reflecting mixed cases of mutagenic exposure or suggesting an alternate mechanism of leukemogenesis in posttransplant leukemia.
If solid organ transplantation and its corresponding therapy promote the development of MNs, which specific therapeutic regimens have major impacts on neoplastic transformation? Due to the heterogeneous treatment modalities and multiple medications used intermittently throughout the latency period, it is challenging to assess for particular regimens accountable for the neoplastic transformation. In their large cohort study, Offman et al 9 reported that the occurrence of MN was correlated with the use of azathioprine, a purine analogue and prodrug for mercaptopurine. They found that the frequency of posttransplant MNs was increased with its dose level within the first year after solid organ transplantation. With experimental studies, the authors demonstrated a clonal population of cells with DNA mismatch repair (MMR) deficiency under azathioprine treatment and suggested that a selective proliferation of an MMR-defective, azathioprine-resistant myeloid clone might contribute to the development of myeloid neoplasms in patients with solid organ transplantation. This hypothetical mechanism of clonal selection is in keeping with the finding by Wong et al 32 in their recent genomic study of therapy-related MNs. In this genomic sequencing analysis, the authors demonstrate a selectively enriched TP53-mutated clone in therapy-related MNs with no considerable increase in genome-wide DNA damage compared with the de novo counterpart. Notably, since US Food and Drug Administration approval of mycophenolate mofetil for use in organ transplantation, the utility of azathioprine in graft maintenance has been steadily declining for the past 2 decades. 33, 34 In our case series, only four (17.4%) patients received azathioprine treatment, including two patients who developed AML and two patients who developed MDS. In most of our cases, mycophenolate mofetil was used in combination with tacrolimus after solid organ transplantation. The question remains: could one or both of these medications act as mutagens to induce myeloid transformation? Mycophenolate mofetil is a prodrug of the active moiety mycophenolate acid that, as a purine analogue, inhibits inosine monophosphate dehydrogenase, the enzyme that controls the rate of synthesis of guanine monophosphate, 35 which is used in the proliferation of B and T lymphocytes. 35, 36 Although antimetabolite agents, including mycophenolate, have been implicated in therapy-related MN, 37 it is uncertain if the doses used for immunosuppression may cause genetic mutation, resulting in the ultimate transformation of hematopoietic precursors. 38 Alternatively, could diminished immunity play a role in leukemogenesis in this population? It is well accepted that impaired immune surveillance attributes to the increased rate of cancers in the aging population and in patients with immunosuppression. The organ-specific rate of posttransplant leukemia suggests that the extent of iatrogenic immunosuppression correlates directly with the development of MNs. 7 Theoretically, decreased immune surveillance would allow an existing neoplastic clone to escape the checkpoint restriction and expand itself by acquiring a proliferative advantage. 39 However, if this is the case, the spectrum of cytogenetic abnormalities in posttransplant leukemia would be expected to be similar to that seen in the de novo counterpart or skewed toward certain types of the leukemia. That pattern of myeloid neoplasia was not observed in our case series, nor has it been reported in the previous cohort studies. 7, 9 Thereafter, impaired immune surveillance may not be a major contributing factor in all cases of MNs developed after solid organ transplantation. Since chemotherapy and radiotherapy-related MNs consist mainly of AML and MDS, whereas therapy-related MPNs are rare, the disproportional fraction of CML and other MPNs in our series and observed in previous studies 7, 13 may suggest alternative mechanisms or a multifactorial pathogenesis in the development of MNs in this particular patient population. This multifactorial mechanism, in addition to defects in immune surveillance against leukemogenesis, 7, 8, 10 may include opportunistic infections and persistent exposure to donor antigens that stimulate chronic proliferation of hematopoietic cells with an increased chance of mutations on critical genes. 8 The latter two hypothetical mechanisms are accepted concepts to describe the development of lymphoid leukemia/lymphoma, such as PTLD, but their roles in the neoplastic transformation of myeloid precursors remain to be investigated. Recent genomic analysis has provided a genomic landscape of MNs, which demonstrates genomic complexities and diversities of MNs. 40, 41 Future work with the genomic analysis of posttransplant leukemia, in comparison with de novo MNs in the general population and conventional therapy-related counterparts, may confer a unique genomic profile and could help identify driver mutations governing leukemia evolution in this patient population.
The clinical outcome of post-solid organ transplant leukemia appears dismal. 7 The survival data in this study are in agreement with those demonstrated by previous analyses, in which an unfavorable outcome has been reported in posttransplant AML/MDS compared with the de novo counterpart. [7] [8] [9] In our analysis and that performed by Morton et al, 7 patients exhibited an initial decline in survival within a few months of initiating chemotherapy, with an estimated median survival of 3.5 months seen in posttransplant AML and an estimated median survival of 7 months (our series) or approximately 12.8 months (Morton et al 7 ) for posttransplant MDS. The precipitous drop observed in the survival curve may suggest an intolerance of chemotherapy or an enhanced toxicity due to drug-drug interactions in this particular patient population. In contrast, the survival of patients with posttransplant CML and other MPNs seems to be favorable as seen in the de novo counterparts, but the exact clinical outcome of these cases remains unclear due to the small number of the cases in the analyses.
